Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

Fig. 4

Representative IFN-gamma cytokine release after stimulation of T-lymphocytes exposed to solitomab vs control BiTE®. A significant increase in IFN-gamma stained cells was consistently detected in both CD8+ or CD4+ T cells (CD8/INF-gamma, CTRL VS BITE, p = 0.001478197; CD4/INF-gamma, CTRL VS BITE, p = 7.84945E-06; CD8/IL4, CTRL VS BITE, p not significant; CD4/IL4, CTRL VS BITE p not significant)

Back to article page